Sagar Lonial, MD

Articles

Dr Lonial on the Impact of the CoMMpass Study on Personalized Medicine in Multiple Myeloma

September 18th 2024

Sagar Lonial, MD, FACP, discusses the broad impact of the CoMMpass study on understanding the molecular underpinnings of multiple myeloma.

Dr Lonial on Characterizing Multiple Myeloma Subtypes in the CoMMpass Study

Sagar Lonial, MD

September 10th 2024

Sagar Lonial, MD, FACP, discusses unique subtypes of multiple myeloma identified through the CoMMpass study.

Dr Lonial on Findings from the CoMMpass Trial in Multiple Myeloma

Sagar Lonial, MD

September 6th 2024

Sagar Lonial, MD, FACP, discusses findings from the CoMMpass trial, which identified high-risk genetic markers in patients with myeloma.

Unmet Needs and Future Perspectives in Multiple Myeloma Care

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

March 13th 2023

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.

Does Belantamab Have a Place in Multiple Myeloma Treatment?

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

March 13th 2023

The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.

Preventing Infection in Patients with Multiple Myeloma During Treatment

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

March 13th 2023

Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.

Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

March 6th 2023

Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.

Targets in Multiple Myeloma: FcRH5

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

March 6th 2023

Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.

Targets in Multiple Myeloma: GPRC5D

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 27th 2023

Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.

Data Updates on Immunotherapy Combinations in Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 27th 2023

Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.

Retreatment with a BCMA-Targeting Bispecific for R/R MM

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 20th 2023

Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.

$BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma$

BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 20th 2023

Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.

CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 13th 2023

The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.

Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 13th 2023

Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.

Quadruplet Combination Therapies in Relapsed Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 6th 2023

Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.

Strategies for Treatment of Multiple Myeloma at Late Relapse

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

February 6th 2023

The panel debates the options for treatment of late relapsed multiple myeloma.

Data Updates in the Treatment of Relapsed Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

January 30th 2023

Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

Relapse in Multiple Myeloma: Biochemical and Chemical

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

January 30th 2023

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

January 23rd 2023

Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

Defining Frailty in Multiple Myeloma for Optimal Treatment

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

January 23rd 2023

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

December 22nd 2022

Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.

Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

Sagar Lonial, MD;Amrita Krishnan, MD;Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center;Hana Safah, MD;Noopur S. Raje, MD

December 22nd 2022

Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.

BCMA-Targeting Therapies for RRMM: Future Perspectives

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 28th 2022

Considerations for optimizing treatment with BCMA-targeting agents for patients with relapsed/refractory multiple myeloma moving forward.

Sequencing BCMA-Targeted Therapies in RRMM

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 28th 2022

Current combination approaches, including BCMA-targeting agents like belantamab mafodotin, being explored to address treatment gaps in relapsed/refractory multiple myeloma.

BCMA-Targeting Bispecifics for the Treatment of RRMM

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 28th 2022

An overview of novel bispecific therapies under development in relapsed/refractory multiple myeloma.

Belantamab Mafodotin Dosing Strategies in Patients with RRMM

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 14th 2022

What to know in terms of dosing belantamab mafodotin treatment in patients with relapsed/refractory multiple myeloma.

Selecting Appropriate Treatment for Patients With Heavily Pretreated Multiple Myeloma

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 14th 2022

Variables that impact treatment decisions for relapsed/refractory multiple myeloma.

Management of a 61-Year-Old Female With Heavily Pretreated RRMM

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 8th 2022

Natalie Callander, MD, presents the profile of a female patient with relapsed/refractory multiple myeloma who receives belantamab mafodotin and develops keratopathy.

Safety of Belantamab Mafodotin in Patients With RRMM

Sagar Lonial, MD;Karen L. Klugo, MD;Natalie Callander, MD

March 8th 2022

Karen L. Klugo, MD, describes what’s unique in terms of patient response to belantamab mafodotin as treatment for relapsed/refractory multiple myeloma and risk of ocular disease.

Dr. Lonial on the Management of Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma

Sagar Lonial, MD

December 8th 2021

Sagar Lonial, MD, FACP, discusses the management of belantamab mafodotin-blmf–related keratopathy in patients with relapsed/refractory multiple myeloma.

1 2 >